Name: 글로벌 시장 동향
SKU: PH1787
Availability: InStock

보고서 요약(국문)

개요
세계 항우울제 시장은 2022년 143억 달러 규모에 달했으며, 2023년부터 2030년까지 연평균 8.7XX%의 성장률을 보이며 2030년에는 206억 달러에 이를 것으로 예상됩니다.
항우울제는 기분과 감정에 관여하는 세로토닌, 노르아드레날린과 같은 신경전달물질의 뇌 내 수치를 증가시켜 작용합니다. 항우울제는 주요 우울 장애, 불안 장애, 월경전 불쾌 장애(PMDD), 양극성 우울증 치료에 사용됩니다.
항우울제는 종종 우울증의 초기 치료제로 처방되며, 증상 관리를 위해 다른 형태의 치료 및 운동과 병행하여 사용될 수 있습니다. 선택적 세로토닌 재흡수 억제제(SSRI)는 가장 흔하게 처방되는 항우울제 계열입니다. 세로토닌 불균형은 우울증의 주요 원인 중 하나이며, SSRI는 뇌에서 세로토닌 재흡수를 감소시켜 우울증 증상을 완화합니다. 또한, 제품 승인 증가, 우울증에 대한 인식 제고, 연구 개발 확대와 같은 주요 성장 동력이 향후 시장 성장을 견인할 것으로 예상됩니다. Eli Lilly and Company, GlaxoSmithKline Plc., LGM Pharma LLC, Apotex Inc. 등 주요 기업들이 활발하게 시장에서 활동하고 있습니다.
시장 동향
항우울제 연구 개발 증가
전 세계 항우울제 시장은 최근 다양한 연구 개발 덕분에 상당한 성장을 보였습니다. 우울증은 일반적으로 병력, 임상 소견 및 영상 검사 결과를 바탕으로 진단됩니다. 또한, 주요 우울 장애 치료에 대한 첨단 연구 개발은 시장 성장을 가속화하는 데 기여하고 있습니다.
예를 들어, 2023년 8월 Novartis AG는 치료 저항성 우울증 치료를 위한 Onfasprodil(MIJ-821)의 2상 임상 개발이 진행 중이라고 발표했습니다. Onfasprodil은 치료 저항성 우울증 및 주요 우울 장애(MDD) 치료에 사용됩니다.

또한, 2022년 11월, 얀센 제약은 치료 저항성 주요 우울 장애(TRD) 성인 환자를 대상으로 선택적 세로토닌 재흡수 억제제(SSRI)와 병용 투여 시 가변 용량 스프라바토(SPRAVATO)와 서방형 쿠에티아핀(XR)의 단기 및 장기 효능, 안전성, 내약성을 비교 평가하기 위해 설계된 장기 무작위 공개 라벨 3b상 임상시험인 ESCAPE-TRD의 결과를 발표했습니다.
연구 데이터에 따르면, 스프라바토로 치료받은 치료 저항성 주요 우울 장애(TRD) 성인 환자는 6주 차부터 유의미하게 높은 관해율을 보였으며, 연구 시작 후 15일째부터 반응률을 나타냈습니다. 따라서 이러한 요인들로 인해 향후 시장 성장이 기대됩니다.

항우울제 승인 증가
항우울제 시장은 의약품 승인 절차의 발전으로 인해 성장할 것으로 예상됩니다. 이러한 발전은 규제 프로세스를 간소화하고, 혁신을 촉진하며, 환자의 치료 접근성을 개선하고, 새롭고 효과적인 우울증 관리 방법을 전 세계적으로 제공하는 데 기여할 것입니다.
예를 들어, 바이오젠(Biogen Inc.)과 세이지 테라퓨틱스(Sage Therapeutics, Inc.)의 공동 발표에 따르면, 2023년 2월 미국 식품의약국(FDA)은 주요 우울 장애(MDD) 및 산후 우울증(PPD) 치료를 위한 주라놀론(zuranolone)의 신약 허가 신청(NDA)을 승인했습니다. MDD 및 PPD를 앓는 성인 환자는 임상시험용 약물인 주라놀론을 14일 동안 하루 한 번 복용합니다.
또한, 2021년 12월에는 닥터 레디스 래버러토리스(Dr. Reddy’s Laboratories)가 벤라팍신 서방정(Venlafaxine ER Tablets)에 대해 미국 식품의약국(FDA)의 승인을 받았습니다. 벤라팍신은 선택적 세로토닌 및 노르에피네프린 재흡수 억제제(SNRI)이며, 벤라팍신 서방정은 주요 우울 장애(MDD) 및 사회 불안 장애(SAD)에 사용됩니다.
항우울제 관련 부작용이 시장 성장을 저해할 수 있습니다.
항우울제는 우울증 치료에 효과적이지만, 메스꺼움, 체중 증가, 성기능 장애, 그리고 드물게는 자살 충동 증가와 같은 불쾌한 부작용을 유발할 수 있습니다. 특히 특정 환자 집단에서 이러한 안전성 문제를 엄격하게 모니터링하고 평가해야 하므로 항우울제 사용이 제한될 수 있습니다.
또한, 항우울제는 잘 알려진 부작용이 적습니다. 그중에는 알코올 내성 감소, 혈소판 응고에 대한 영향으로 인한 출혈 위험 증가, 그리고 혈중 나트륨 수치에 대한 잠재적 영향으로 인한 두통이나 혼란과 같은 증상이 있습니다.

세그먼트 분석
전 세계 항우울제 시장은 약물 종류, 우울증 유형, 유통 채널 및 지역별로 세분화됩니다.
약물 종류별 세그먼트에서 선택적 세로토닌 재흡수 억제제(SSRI)는 전 세계 항우울제 시장 점유율의 약 XX%를 차지했습니다.
SSRI 치료제에 대한 임상 시험이 증가함에 따라 SSRI는 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 우울증 치료를 위해 총 933건의 임상 시험이 수행되었습니다. 예를 들어, clinicalTrials.gov에 따르면 2023년 7월 13일 미네소타 대학교는 청소년 우울증 치료를 위한 적응형 알고리즘 기반 접근법에 대한 임상 시험을 진행했습니다. 이 연구의 목적은 청소년 우울증에 대한 두 가지 적응형 치료 전략(ATS)의 효과를 평가하는 것입니다. 이 치료법에는 플루옥세틴, 에스시탈로프람, 시탈로프람, 플루복사민 또는 세르트랄린과 같은 선택적 세로토닌 재흡수 억제제(SSRI) 약물이 포함됩니다.
또한, 2023년 8월 16일, 얀센 리서치 앤 디벨로핑(Janssen Research & Development, LLC)은 주요 우울 장애가 있는 성인 및 노인 참가자를 대상으로 아티카프란트 임상 시험을 실시했습니다. 이 연구의 목적은 주요 우울 장애(MDD) 환자 전체에서 현재 복용 중인 항우울제(선택적 세로토닌 재흡수 억제제)에 대한 보조 요법으로 투여되는 아티카프란트의 장기적인 안전성과 내약성을 평가하는 것입니다.
지역별 시장 점유율
북미는 2022년 시장 점유율의 약 38.4%를 차지했습니다.
세계 항우울제 시장은 북미, 유럽, 아시아 태평양, 남미, 중동 및 아프리카로 구분됩니다. 최근 몇 년간 북미는 항우울제 시장에서 상당한 점유율을 유지해 왔으며, FDA 승인 증가와 항우울제 연구 개발 등의 요인으로 인해 이러한 추세는 예측 기간 동안 지속될 것으로 예상됩니다.
예를 들어, 중추신경계(CNS) 질환 치료를 위한 신약 개발 전문 바이오제약 회사인 액솜 테라퓨틱스(Axsome Therapeutics, Inc.)는 2022년 8월, 아우벨리티(AUVELITY, 덱스트로메토르판 HBr - 부프로피온 HCl) 서방정의 FDA 승인을 받았습니다. 이로써 아우벨리티는 성인 주요 우울 장애(MDD) 치료에 승인된 최초이자 유일한 경구용 N-메틸 D-아스파르트산(NMDA) 수용체 길항제가 되었습니다.
또한, 애브비(AbbVie)에 따르면, 2022년 12월 FDA는 성인 주요 우울 장애(MDD) 치료를 위한 항우울제 보조 요법으로 브레이라(VRAYLAR, 카리프라진)를 승인했습니다. 카리프라진은 미국에서 VRAYLAR라는 상품명으로 판매되며, 성인의 우울증, 급성 조증, 양극성 장애 1형과 관련된 혼합 삽화 및 정신분열증 치료에 FDA 승인을 받았을 뿐만 아니라, 주요 우울 장애(MDD) 치료를 위한 항우울제 보조 요법으로도 승인되었습니다.
경쟁 환경
주요 글로벌 시장 참여 기업으로는 Eli Lilly and Company, GlaxoSmithKline Plc., LGM Pharma LLC, Apotex Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., AstraZeneca Plc., Takeda Pharmaceutical Co. Ltd, Pfizer Inc., Aurobindo Pharma Limited, Merck KGaA 등이 있습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 항우울제 시장에 상당한 영향을 미쳤습니다. 팬데믹이 한창일 때 많은 의료 시스템이 과부하 상태에 빠졌고, 긴급하지 않은 의료 시술 및 검진이 연기되거나 취소되었습니다. 이로 인해 항우울제 연구 및 제품 출시가 지연되었습니다. 임상 시험은 항우울제 시장에서 새로운 치료법을 개발하고 치료 결과를 개선하는 데 필수적입니다.
그러나 팬데믹으로 인해 임상 시험 진행에 차질이 생겼고, 많은 기관에서 환자 안전을 최우선으로 고려하여 등록을 일시적으로 중단하거나 프로토콜을 변경했습니다. 이로 인해 시험 완료 및 새로운 치료법의 출시가 지연되었습니다. 더욱이, 팬데믹 기간 동안 연구 개발 노력의 초점이 코로나19 백신 및 치료제 개발에 집중되면서 다른 분야로 옮겨갔습니다. 따라서 이러한 요인들로 인해 항우울제 시장은 예측 기간 동안 다소 영향을 받을 것으로 예상됩니다.

약물 종류별
• 모노아민 산화효소 억제제
o 이소카르복사지드
o 페넬진
o 셀레길린
o 트라닐시프로민
• 노르에피네프린-도파민 재흡수 억제제
o 아미넵틴
o 부프로피온
o 데속시피프라드롤
o 덱스메틸페니데이트
o 디페메토렉스
• 세로토닌-노르에피네프린 재흡수 억제제
o 데스벤라팍신
o 둘록세틴
o 레보밀나시프란
o 밀나시프란
o 벤라팍신
• 선택적 세로토닌 재흡수 억제제
o 시탈로프람
o 에스시탈로프람
o 플루옥세틴
o 파록세틴
o 세르트랄린
• 삼환계 항우울제
o 아미트립틸린
o 아목사핀
o 데시프라민
o 독세핀
o 이미프라민
노르트립틸린
우울 장애별 분류
• 주요 우울 장애
• 강박 장애
• 범불안 장애
• 공황 장애
• 기타
유통 채널별 분류
• 병원 약국
• 소매 약국
• 온라인 약국
• 기타
지역별 분류
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발 사항
• 2023년 3월, 알렘빅 파마슈티컬스는 미국 식품의약국(FDA)으로부터 브렉스피프라졸 정제 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg의 판매 승인을 받았습니다. 브렉스피프라졸 정제는 주요 우울 장애 치료를 위한 항우울제 보조 요법으로 사용됩니다.
• 2022년 11월, 루예제약그룹(Luye Pharma Group)은 중국 국가약품감독관리국(NMPA)으로부터 주요 우울 장애 환자 치료를 위한 삼중 모노아민 재흡수 억제제인 루오신린(톨루데스벤라팍신 염산염)의 판매 승인을 받았습니다.
보고서 구매 이유:

• 약물 종류, 우울 장애 유형, 유통 채널 및 지역별 글로벌 항우울제 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 글로벌 항우울제 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품 정보를 담은 엑셀 파일 형태의 제품 맵핑을 제공합니다.

글로벌 항우울제 시장 보고서는 약 69개의 표, 70개의 그림, 그리고 195페이지 분량으로 구성될 예정입니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Antidepressant Drugs Market reached US$ 14.3 billion in 2022 and is expected to reach US$ 20.6 billion by 2030 growing with a CAGR of 8.7XX% during the forecast period 2023-2030.
Antidepressant drugs work by increasing levels of chemicals in the brain called neurotransmitters such as serotonin and noradrenaline that are linked to mood and emotion. Antidepressants are used to treat major depressive disorder, anxiety disorders, premenstrual dysphoric disorder (PMDD), and bipolar depression.
Antidepressants are often prescribed as the initial treatment for depression and can be used with other forms of therapy and exercise to manage symptoms. SSRIs (Selective serotonin reuptake inhibitors) are the most commonly prescribed class of antidepressants. An imbalance of serotonin can play a role in depression and these drugs fight depression symptoms by decreasing serotonin reuptake in the brain.
Furthermore, significant growth drivers such as increasing product approvals, awareness of depressive disorders, and research and developments give rise to future market growth. Significant key players like Eli Lilly and Company, GlaxoSmithKline Plc., LGM Pharma LLC, Apotex Inc., and others are actively operating in the market.
Dynamics
Increasing Research and Developments for Antidepressant Drugs
The global antidepressant drugs market has witnessed significant growth due to various recent research and developments. Depression is usually diagnosed on the basis of medical history and clinical and imaging findings. Also, advanced research and developments in treating major depressive disorder help to accelerate market growth.
For instance, in August 2023, Novartis AG declared that the drug Onfasprodil is under clinical development Phase II for Treatment Resistant Depression. Onfasprodil (MIJ-821) is used for the treatment of treatment-resistant depression, and major depressive disorder (MDD).
Additionally, in November 2022, Janssen Pharmaceutical declared the results from ESCAPE-TRD, a long-term, randomized, open-label phase 3b designed to evaluate the short- and long-term efficacy, safety and tolerability of flexibly dosed SPRAVATO compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake inhibitor (SSRI) in adults with treatment-resistant major depressive disorder (TRD).
The data shows that adults with treatment-resistant major depressive disorder (TRD) treated with SPRAVATO achieved significantly higher remission rates from Week 6 and response rates as early as day 15 in the study. Thus, due to the above factors, the market is expected to boost over the forecast period.
Increasing Approvals for Antidepressant Drugs
The global market for antidepressant drugs is anticipated to be driven by advancements in drug approval procedures which will streamline regulatory processes, stimulate innovation, improve patient access to therapies, and facilitate the availability of novel and efficient depression management choices globally.
For instance, in February 2023, the FDA approved the submission of a New Drug Application (NDA) for zuranolone for the treatment of major depressive disorder (MDD) and postpartum depression (PPD), according to a joint statement from Biogen Inc. and Sage Therapeutics, Inc. Adults with MDD and PPD are being treated with the investigational drug zuranolone once daily for 14 days.
In December 2021, Dr. Reddy’s Laboratories received U.S. Food and Drug Administration (USFDA) approval for Venlafaxine ER Tablets. It is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and Venlafaxine Extended Release tablets are indicated for major depressive disorder (MDD) and social anxiety disorder (SAD).
Side Effects Associated with Treatment Drugs will Hamper the Growth of the Market
Antidepressant medications work well to treat depression, but they can also have unpleasant side effects like nausea, weight gain, sexual dysfunction, and, in a small percentage of cases, a higher risk of suicidal thoughts. Antidepressant drug uptake may be constrained by the need for rigorous monitoring and evaluation of these safety issues, particularly in certain patient populations.
In addition, antidepressant medications have fewer well-known adverse effects. Among them are a decreased tolerance to alcohol, a raised risk of bleeding due to effects on platelet clotting, and potential interference with blood sodium levels, which could cause symptoms like headaches or confusion.
Segment Analysis
The global antidepressant drugs market is segmented based on drug class, depression disorder, distribution channel, and region.
Selective Serotonin Reuptake Inhibitors from the Drug Class Segment Accounted for Approximately XX% of the Global Antidepressant Drugs Market Share
Selective Serotonin Reuptake Inhibitor is expected to hold the largest market share over the period forecast owing to increasing clinical trials of SSRI treatment drugs. A total of 933 clinical trials were performed for the treatment of depression. For instance, according to clinicalTrials.gov, on July 13, 2023, the University of Minnesota conducted a clinical trial on the Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression. The purpose of this study is to evaluate the effectiveness of two adaptive treatment strategies (ATSs) for adolescent depression. The intervention involves selective serotonin reuptake inhibitor drugs like Fluoxetine, escitalopram, citalopram, fluvoxamine, or sertraline.
Additionally, on August 16, 2023, Janssen Research & Development, LLC conducted a clinical trial on the Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder. The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor) in all participants with major depressive disorder (MDD).
Geographical Penetration
North America Accounted for Approximately 38.4% of the Market Share in 2022
The global antidepressant drugs market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. North America has maintained a significant proportion of the antidepressant drugs market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising FDA approvals, and research and developments in antidepressant drugs.
For instance, in August 2022, Axsome Therapeutics, Inc., a biopharmaceutical company specializing in novel therapeutics for central nervous system (CNS) disorders, got FDA approval for AUVELITY (dextromethorphan HBr - bupropion HCl) extended-release tablets. With this approval, AUVELITY becomes the first and only oral N-methyl D-aspartate (NMDA) receptor antagonist approved for the treatment of major depressive disorder (MDD) in adults.
Additionally, in December 2022, the FDA approved VRAYLAR (cariprazine) as an adjuvant therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults, according to AbbVie. Cariprazine is marketed as VRAYLAR in the U.S., and it is FDA-approved to treat adults with depressive, acute manic, and mixed episodes associated with bipolar I disorder, as well as schizophrenia, in addition to being approved as an adjunctive therapy to antidepressants for treatment of MDD.
Competitive Landscape
The major global players in the market include Eli Lilly and Company, GlaxoSmithKline Plc., LGM Pharma LLC, Apotex Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., AstraZeneca Plc., Takeda Pharmaceutical Co. Ltd, Pfizer Inc., Aurobindo Pharma Limited, and Merck KGaA among others.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the global antidepressant drugs market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in antidepressant drug research and product launches. Clinical trials are vital for developing new treatments and improving outcomes in the antidepressant drugs market.
However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the antidepressant drugs market is expected to be moderately affected over the forecast period.
By Drug Class
• Monoamine Oxidase Inhibitors
o Isocarboxazid
o Phenelzine
o Selegiline
o Tranylcypromine
• Norepinephrine-Dopamine Reuptake Inhibitor
o Amineptine
o Bupropion
o Desoxypipradrol
o Dexmethylphenidate
o Difemetorex
• Serotonin-Norepinephrine Reuptake Inhibitors
o Desvenlafaxine
o Duloxetine
o Levomilnacipran
o Milnacipran
o Venlafaxine
• Selective Serotonin Reuptake Inhibitors
o Citalopram
o Escitalopram
o Fluoxetine
o Paroxetine
o Sertraline
• Tricyclic Antidepressants
o Amitriptyline
o Amoxapine
o Desipramine
o Doxepin
o Imipramine
o Nortriptyline
By Depression Disorder
• Major Depressive Disorder
• Obsessive-Compulsive Disorder
• Generalized Anxiety Disorder
• Panic Disorder
• Others
By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In March 2023, Alembic Pharmaceuticals received approval from the US Food & Drug Administration to market Brexpiprazole tablets in strengths of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg. Brexpiprazole tablets are indicated as an adjunctive therapy to antidepressants for the treatment of major depressive disorder.
• In November 2022, Luye Pharma Group received marketing approval from China’s NMPA for the triple monoamine reuptake inhibitor Ruoxinlin (toludesvenlafaxine hydrochloride) to treat patients with major depressive disorder.
Why Purchase the Report?
• To visualize the global antidepressant drugs market segmentation based on drug class, depression disorder, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global antidepressant drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global antidepressant drugs market report would provide approximately 69 tables, 70 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Depression Disorder
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Research and Developments for Antidepressant Drugs
4.1.1.2. Increasing Approvals for Antidepressant Drugs
4.1.2. Restraints
4.1.2.1. Side Effects Associated with Treatment Drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Monoamine Oxidase Inhibitors
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Isocarboxazid
7.2.4. Phenelzine
7.2.5. Selegiline
7.2.6. Tranylcypromine
7.3. Norepinephrine-Dopamine Reuptake Inhibitor
7.3.1. Amineptine
7.3.2. Bupropion
7.3.3. Desoxypipradrol
7.3.4. Dexmethylphenidate
7.3.5. Difemetorex
7.4. Serotonin-Norepinephrine Reuptake Inhibitors
7.4.1. Desvenlafaxine
7.4.2. Duloxetine
7.4.3. Levomilnacipran
7.4.4. Milnacipran
7.4.5. Venlafaxine
7.5. Selective Serotonin Reuptake Inhibitors
7.5.1. Citalopram
7.5.2. Escitalopram
7.5.3. Fluoxetine
7.5.4. Paroxetine
7.5.5. Sertraline
7.6. Tricyclic Antidepressants
7.6.1. Amitriptyline
7.6.2. Amoxapine
7.6.3. Desipramine
7.6.4. Doxepin
7.6.5. Imipramine
7.6.6. Nortriptyline
7.6.7. Others
8. By Depression Disorder
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Depression Disorder
8.1.2. Market Attractiveness Index, By Depression Disorder
8.2. Major Depressive Disorder
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Obsessive-Compulsive Disorder
8.4. Generalized Anxiety Disorder
8.5. Panic Disorder
8.6. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacy
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacy
9.4. Online Pharmacy
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Depression Disorder
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Depression Disorder
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Depression Disorder
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Depression Disorder
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Depression Disorder
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Product Benchmarking
11.3. Company Share Analysis
11.4. Key Developments and Strategies
12. Company Profiles
12.1. Eli Lilly and Company*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. GlaxoSmithKline Plc.
12.3. LGM Pharma LLC
12.4. Apotex Inc.
12.5. Zheijiang Huahai Pharmaceutical Co. Ltd.
12.6. AstraZeneca Plc.
12.7. Takeda Pharmaceutical Co. Ltd
12.8. Pfizer Inc.
12.9. Aurobindo Pharma Limited
12.10. Merck KGaA
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Eli Lilly and Company, 4.	Key Developments, GlaxoSmithKline Plc., LGM Pharma LLC, Apotex Inc., Zheijiang Huahai Pharmaceutical Co. Ltd., AstraZeneca Plc., Takeda Pharmaceutical Co. Ltd, Pfizer Inc., Aurobindo Pharma Limited, Merck KGaA

표 목록 (Tables)

List of Tables

Table 1 Global Antidepressant Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Antidepressant Drugs Market Value, By Depression Disorder, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Antidepressant Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Antidepressant Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Antidepressant Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Antidepressant Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 7 Global Antidepressant Drugs Market Value, By Depression Disorder, 2022, 2026 & 2030 (US$ Billion)

Table 8 Global Antidepressant Drugs Market Value, By Depression Disorder, 2021-2030 (US$ Billion)

Table 9 Global Antidepressant Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 10 Global Antidepressant Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 11 Global Antidepressant Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 12 Global Antidepressant Drugs Market Value, By Region, 2021-2030 (US$ Billion)

Table 13 North America Antidepressant Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 14 North America Antidepressant Drugs Market Value, By Depression Disorder, 2021-2030 (US$ Billion)

Table 15 North America Antidepressant Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 16 North America Antidepressant Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 17 South America Antidepressant Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 18 South America Antidepressant Drugs Market Value, By Depression Disorder, 2021-2030 (US$ Billion)

Table 19 South America Antidepressant Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 20 South America Antidepressant Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 Europe Antidepressant Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 22 Europe Antidepressant Drugs Market Value, By Depression Disorder, 2021-2030 (US$ Billion)

Table 23 Europe Antidepressant Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 24 Europe Antidepressant Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 25 Asia-Pacific Antidepressant Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 26 Asia-Pacific Antidepressant Drugs Market Value, By Depression Disorder, 2021-2030 (US$ Billion)

Table 27 Asia-Pacific Antidepressant Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 28 Asia-Pacific Antidepressant Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 29 Middle East & Africa Antidepressant Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 30 Middle East & Africa Antidepressant Drugs Market Value, By Depression Disorder, 2021-2030 (US$ Billion)

Table 31 Middle East & Africa Antidepressant Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 32 Eli Lilly and Company: Overview

Table 33 Eli Lilly and Company: Product Portfolio

Table 34 Eli Lilly and Company: Key Developments

Table 35 GlaxoSmithKline Plc.: Overview

Table 36 GlaxoSmithKline Plc.: Product Portfolio

Table 37 GlaxoSmithKline Plc.: Key Developments

Table 38 LGM Pharma LLC: Overview

Table 39 LGM Pharma LLC: Product Portfolio

Table 40 LGM Pharma LLC: Key Developments

Table 41 Apotex Inc.: Overview

Table 42 Apotex Inc.: Product Portfolio

Table 43 Apotex Inc.: Key Developments

Table 44 Zheijiang Huahai Pharmaceutical Co. Ltd.: Overview

Table 45 Zheijiang Huahai Pharmaceutical Co. Ltd.: Product Portfolio

Table 46 Zheijiang Huahai Pharmaceutical Co. Ltd.: Key Developments

Table 47 AstraZeneca Plc.: Overview

Table 48 AstraZeneca Plc.: Product Portfolio

Table 49 AstraZeneca Plc.: Key Developments

Table 50 Takeda Pharmaceutical Co. Ltd: Overview

Table 51 Takeda Pharmaceutical Co. Ltd: Product Portfolio

Table 52 Takeda Pharmaceutical Co. Ltd: Key Developments

Table 53 Pfizer Inc.: Overview

Table 54 Pfizer Inc.: Product Portfolio

Table 55 Pfizer Inc.: Key Developments

Table 56 Aurobindo Pharma Limited: Overview

Table 57 Aurobindo Pharma Limited: Product Portfolio

Table 58 Aurobindo Pharma Limited: Key Developments

Table 59 Merck KGaA: Overview

Table 60 Merck KGaA: Product Portfolio

Table 61 Merck KGaA: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Antidepressant Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 3 Global Antidepressant Drugs Market Share, By Depression Disorder, 2022 & 2030 (%)

Figure 4 Global Antidepressant Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Antidepressant Drugs Market Share, By , 2022 & 2030 (%)

Figure 6 Global Antidepressant Drugs Market Share, By , 2022 & 2030 (%)

Figure 7 Global Antidepressant Drugs Market Share, By , 2022 & 2030 (%)

Figure 8 Global Antidepressant Drugs Market Share, By , 2022 & 2030 (%)

Figure 9 Global Antidepressant Drugs Market Share, By Region, 2022 & 2030 (%)

Figure 10 Global Antidepressant Drugs Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 11 Monoamine Oxidase Inhibitors Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 12 Norepinephrine-Dopamine Reuptake Inhibitor Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 13 Serotonin-Norepinephrine Reuptake Inhibitors Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 14 Selective Serotonin Reuptake Inhibitors Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 15 Tricyclic Antidepressants Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 16 Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 17 Global Antidepressant Drugs Market Y-o-Y Growth, By Depression Disorder, 2022-2030 (%)

Figure 18 Major Depressive Disorder Depression Disorder in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 19 Obsessive-Compulsive Disorder Depression Disorder in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 20 Generalized Anxiety Disorder Depression Disorder in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 21 Panic Disorder Depression Disorder in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 22 Others Depression Disorder in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 23 Depression Disorder in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 24 Depression Disorder in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 25 Global Antidepressant Drugs Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 26 Hospital Pharmacy Distribution Channel in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 27 Retail Pharmacy Distribution Channel in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 28 Online Pharmacy Distribution Channel in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 29 Others Distribution Channel in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 30 Global Antidepressant Drugs Market Y-o-Y Growth, By , 2022-2030 (%)

Figure 31 in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 32 in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 33 in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 34 in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 35 Global Antidepressant Drugs Market Y-o-Y Growth, By , 2022-2030 (%)

Figure 36 in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 37 in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 38 in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 39 in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 40 Global Antidepressant Drugs Market Y-o-Y Growth, By , 2022-2030 (%)

Figure 41 in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 42 in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 43 in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 44 in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 45 Global Antidepressant Drugs Market Y-o-Y Growth, By , 2022-2030 (%)

Figure 46 in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 47 in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 48 in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 49 in Global Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 50 Global Antidepressant Drugs Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 51 North America Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 52 Asia-Pacific Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 53 Europe Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 54 South America Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 55 Middle East and Africa Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 56 North America Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 57 North America Antidepressant Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 58 North America Antidepressant Drugs Market Share, By Depression Disorder, 2022 & 2030 (%)

Figure 59 North America Antidepressant Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 60 North America Antidepressant Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 61 South America Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 62 South America Antidepressant Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 63 South America Antidepressant Drugs Market Share, By Depression Disorder, 2022 & 2030 (%)

Figure 64 South America Antidepressant Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 65 South America Antidepressant Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 66 Europe Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 67 Europe Antidepressant Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 68 Europe Antidepressant Drugs Market Share, By Depression Disorder, 2022 & 2030 (%)

Figure 69 Europe Antidepressant Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 70 Europe Antidepressant Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 71 Asia-Pacific Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 72 Asia-Pacific Antidepressant Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 73 Asia-Pacific Antidepressant Drugs Market Share, By Depression Disorder, 2022 & 2030 (%)

Figure 74 Asia-Pacific Antidepressant Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 75 Asia-Pacific Antidepressant Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 76 Middle East & Africa Antidepressant Drugs Market Value, 2021-2030 (US$ Billion)

Figure 77 Middle East & Africa Antidepressant Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 78 Middle East & Africa Antidepressant Drugs Market Share, By Depression Disorder, 2022 & 2030 (%)

Figure 79 Middle East & Africa Antidepressant Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 80 Eli Lilly and Company: Financials

Figure 81 GlaxoSmithKline Plc.: Financials

Figure 82 LGM Pharma LLC: Financials

Figure 83 Apotex Inc.: Financials

Figure 84 Zheijiang Huahai Pharmaceutical Co. Ltd.: Financials

Figure 85 AstraZeneca Plc.: Financials

Figure 86 Takeda Pharmaceutical Co. Ltd: Financials

Figure 87 Pfizer Inc.: Financials

Figure 88 Aurobindo Pharma Limited: Financials

Figure 89 Merck KGaA: Financials

세계 항우울제 시장 – 2023-2030

Global Antidepressant Drugs Market - 2023-2030